MedTrace Logo

The Effect of Vitamin D Supplementation on Psoriasis Severity

NCT03334136 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2020-10-08

No results posted yet for this study

Summary

The study evaluates the effect of oral vitamin D supplementation on the severity of psoriasis measured by Psoriasis Area Severity Index (PASI) in adults with lower vitamin D levels. Half of the participants will receive vitamin D, while the other half receive placebo.

Conditions

Interventions

DRUG

25-Hydroxyvitamin D

Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)

DRUG

Placebo oral capsule

Five capsules the first day and thereafter one capsule every week for 4 months.

Sponsors & Collaborators

  • The Royal Norwegian Ministry of Health

    collaborator OTHER

  • University of Tromso

    collaborator OTHER

  • Cornell University

    collaborator OTHER

  • University Hospital of North Norway

    lead OTHER

Principal Investigators

  • Kjersti Danielsen, MD, PhD · University Hospital of North Norway

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-24
Primary Completion
2019-05-13
Completion
2019-05-13

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334136 on ClinicalTrials.gov